- ISIN
- US30233G2093
- CUSIP
- 74439M107
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 27, 2005
Highlights
- EPS (TTM)
- -$3.12
- Total Revenue (TTM)
- $31.37M
- Gross Profit (TTM)
- $29.31M
- EBITDA (TTM)
- -$239.53M
- Year Range
- $8.88 - $19.11
- Target Price
- $37.50
- ROA (TTM)
- -80.48%
- ROE (TTM)
- -100.65%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
EYPT Performance Chart
Eyepoint Pharmaceuticals Inc (EYPT) is down 24.9% since the beginning of the year. At $14 per share, EYPT is trading 28.2% below its 52-week high of $19. Investors who bought $1,000 worth of EYPT shares 5 years ago would now be looking at an investment worth $1,430.
Loading charts...
Returns By Period
Eyepoint Pharmaceuticals Inc (EYPT) has returned -24.85% so far this year and 63.06% over the past 12 months. Over the last ten years, EYPT has returned -7.76% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Eyepoint Pharmaceuticals Inc
- 1D
- 1.10%
- 1M
- 6.19%
- YTD
- -24.85%
- 6M
- -27.16%
- 1Y
- 63.06%
- 3Y*
- 26.58%
- 5Y*
- 7.42%
- 10Y*
- -7.76%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
EYPT Monthly Returns History
Based on dividend-adjusted daily data since Jan 27, 2005, EYPT's average daily return is +0.13%, while the average monthly return is +2.47%. At this rate, an investment would double in approximately 2.4 years.
Historically, 44% of months were positive and 56% were negative. The best month was Dec 2023 with a return of +269.8%, while the worst month was Nov 2011 at -68.6%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 10 months.
On a daily basis, EYPT closed higher 44% of trading days. The best single day was Jun 11, 2008 with a return of +232.6%, while the worst single day was Nov 11, 2011 at -48.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -26.00% | 29.88% | -26.59% | 2.40% | 2.88% | 1.10% | -24.85% | ||||||
| 2025 | 2.68% | -18.04% | -13.56% | 25.83% | 6.16% | 29.97% | 4.36% | 17.82% | 23.08% | -8.08% | 13.29% | 23.20% | 145.23% |
| 2024 | 16.53% | 1.04% | -24.04% | -14.85% | -39.15% | -18.77% | 13.56% | -9.41% | -10.73% | 47.18% | -24.74% | -15.82% | -67.76% |
| 2023 | 33.14% | -28.33% | -11.98% | 113.61% | -3.66% | 43.80% | 43.68% | -20.72% | -19.37% | -24.66% | 3.82% | 269.76% | 560.29% |
| 2022 | -23.45% | 6.19% | 22.11% | -7.00% | -14.60% | -18.45% | 16.01% | 9.53% | -20.90% | -31.73% | -40.74% | 9.38% | -71.41% |
| 2021 | 70.21% | -3.48% | -6.01% | 5.22% | -8.04% | -8.55% | -8.57% | 33.09% | -4.75% | 10.08% | 37.75% | -22.53% | 86.02% |
Benchmark Metrics
Eyepoint Pharmaceuticals Inc has an annualized alpha of 26.95%, beta of 0.88, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since January 27, 2005.
- This stock participated in 161.29% of S&P 500 Index downside but only 85.91% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 26.95%
- Beta
- 0.88
- R²
- 0.03
- Upside Capture
- 85.91%
- Downside Capture
- 161.29%
Return for Risk
Risk / Return Rank
EYPT ranks 70 for risk / return — better than 70% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Eyepoint Pharmaceuticals Inc (EYPT) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| EYPT | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.09 | ||
| Sortino ratioReturn per unit of downside risk | -1.04 | ||
| Omega ratioGain probability vs. loss probability | 1.20 | 1.37 | -0.17 |
| Calmar ratioReturn relative to maximum drawdown | 1.61 | 2.78 | -1.17 |
| Martin ratioReturn relative to average drawdown | 3.32 | 12.44 | -9.12 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Eyepoint Pharmaceuticals Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Eyepoint Pharmaceuticals Inc was 97.83%, occurring on Mar 24, 2023. The portfolio has not yet recovered.
The current Eyepoint Pharmaceuticals Inc drawdown is 86.92%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -97.83%Mar 2023 | 18y 2mo | — | 21y 5moJan 2005 - now |
Drawdown Indicators
| EYPT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.83% | -56.78% | -41.05% |
Max Drawdown (1Y)Largest decline over 1 year | -39.26% | -9.10% | -30.16% |
Max Drawdown (3Y)Largest decline over 3 years | -86.10% | -18.90% | -67.20% |
Max Drawdown (5Y)Largest decline over 5 years | -87.61% | -25.43% | -62.18% |
Max Drawdown (10Y)Largest decline over 10 years | -94.45% | -33.92% | -60.53% |
Current DrawdownCurrent decline from peak | -86.92% | -1.80% | -85.12% |
Average DrawdownAverage peak-to-trough decline | -77.46% | -10.71% | -66.75% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.05% | 2.03% | +17.02% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Eyepoint Pharmaceuticals Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Eyepoint Pharmaceuticals Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for EYPT relative to other companies in the Biotechnology industry. Currently, EYPT has a P/S ratio of 32.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with EYPT
Add Eyepoint Pharmaceuticals Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with EYPT